title: Lubiprostone for treatment-resistant constipation associated with clozapine use.
authors.affiliation: Psychopharmacology Resource Network, Patton State Hospital, Patton, CA, USA; Mental Health Intensive Case Management, VA San Diego Healthcare System, Loma Linda University School of Medicine, Loma Linda, CA, USA; University of California, San Diego School of Medicine, San Diego, CA, USA. jonathan.meyer@psh.dsh.ca.gov.
authors.forename: J M
authors.initials: JM
authors.lastname: Meyer
authors.forename: M A
authors.initials: MA
authors.lastname: Cummings
mesh_terms: D000328:Adult; D000527:Alprostadil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D065101:Chloride Channel Agonists / Q000627:therapeutic use*; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D003248:Constipation / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D000068238:Lubiprostone; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy; D017211:Treatment Failure
chemical_list: D014150:Antipsychotic Agents; D065101:Chloride Channel Agonists; D000068238:Lubiprostone; D000527:Alprostadil; D003024:Clozapine